FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.
Brun, Eva LU ; Kjellén, Elisabeth LU ; Tennvall, Jan LU ; Ohlsson, Tomas G LU ; Sandell, Anders LU ; Perfekt, Roland LU ; Wennerberg, Johan LU
and Strand, Sven-Erik
LU
(2002)
In Head and Neck
24(2).
p.127-135
- Abstract
- BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete... (More)
- BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/106026
- author
- Brun, Eva
LU
; Kjellén, Elisabeth
LU
; Tennvall, Jan
LU
; Ohlsson, Tomas G
LU
; Sandell, Anders
LU
; Perfekt, Roland
LU
; Wennerberg, Johan
LU
and Strand, Sven-Erik
LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics, Female, Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy, Human, Male, Middle Age, Predictive Value of Tests, Reproducibility of Results, Radiopharmaceuticals/*diagnostic use/pharmacokinetics, Squamous Cell/mortality/*radionuclide imaging/*therapy, Carcinoma, 80 and over, Aged
- in
- Head and Neck
- volume
- 24
- issue
- 2
- pages
- 127 - 135
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:11891942
- wos:000173623500003
- scopus:0036154720
- ISSN
- 1043-3074
- DOI
- 10.1002/hed.10037
- language
- English
- LU publication?
- yes
- id
- 5cb8efc7-dd78-4119-8426-fbcad0dbd082 (old id 106026)
- alternative location
- http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11891942&dopt=Abstract
- date added to LUP
- 2016-04-01 12:02:54
- date last changed
- 2022-04-28 23:50:38
@article{5cb8efc7-dd78-4119-8426-fbcad0dbd082,
abstract = {{BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc.}},
author = {{Brun, Eva and Kjellén, Elisabeth and Tennvall, Jan and Ohlsson, Tomas G and Sandell, Anders and Perfekt, Roland and Wennerberg, Johan and Strand, Sven-Erik}},
issn = {{1043-3074}},
keywords = {{Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics; Female; Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy; Human; Male; Middle Age; Predictive Value of Tests; Reproducibility of Results; Radiopharmaceuticals/*diagnostic use/pharmacokinetics; Squamous Cell/mortality/*radionuclide imaging/*therapy; Carcinoma; 80 and over; Aged}},
language = {{eng}},
number = {{2}},
pages = {{127--135}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Head and Neck}},
title = {{FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.}},
url = {{http://dx.doi.org/10.1002/hed.10037}},
doi = {{10.1002/hed.10037}},
volume = {{24}},
year = {{2002}},
}